Daiwa Securities Group
CPRX icon

Daiwa Securities Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Daiwa Securities Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,200
Closed -$158K – 1291
2024
Q2 		$158K Sell
10,200
-11,200
-52% -$174K ﹤0.01% 991
2024
Q1 		$341K Buy
+21,400
New +$322K ﹤0.01% 897

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Daiwa Securities Group's CPRX Position: Q3 2024 in Review

Daiwa Securities Group sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 10,200 shares — an estimated $158K sold.

Daiwa Securities Group first reported a position in CPRX in Q1 2024 and held it in 2 quarters. The position peaked at $341K in Q1 2024. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

  • Daiwa Securities Group reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Daiwa Securities Group sold 10,200 Catalyst Pharmaceutical shares in Q3 2024, an estimated $158K.
  • Daiwa Securities Group first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 2 quarters.
  • Daiwa Securities Group's Catalyst Pharmaceutical position peaked at $341K in Q1 2024.
  • 316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Daiwa Securities Group's 13F filing for Q3 2024, filed 12 Nov 2024.